Epitech Group S.r.l.

Innovet Italia S.r.l.

Epitech Group S.p.a.

Consiglio Nazionale Delle Richerche

Ivg Colbachini S.p.a.

I.r.b. Istituto Di Ricerche Biotechnologiche S.r.l.

Centro Studi Termali Veneto Pietro D'abano Di Abano Terme Montegrotto Terme

Gabriele Marcolongo

Francesco Della Valle

Maria Federica Della Valle

Salvatore Cuzzocrea

Vincenzo Di Marzo

Vito Safina

Cristina Comelli

Chiara Gomiero

Luciano De Petrocellis

Roberto Dal Toso

Roberto Russo

Giuseppe D'Agostino

Sofia Parrasia

Annalisa Noce

Giuseppe Esposito

Giuliano Claps

Daniele Grassi

Barbara Costa

Stefania Petrosino

Tiziana Bisogno

Antonio Calignano

Sonia Laneri

Rosaria Meli

Dominique Melck

Carmine Ostacolo

Antonia Sacchi

Diana Tronino

Moreno Meneghetti

Daniela Corda

Giovanna Bonvento

Renzo Dal Monte

Francesca De Appolonia

Alberto Lalli

Cristina Ceschi Berrini

Carlo Andreoli

Gianpiero Ravagnan

Giuseppe D'agostino

Federica Della Valle

Claudia Cristiano

The present invention relates to a method of treating a COVID-19 infection by administering an effective amount of an endogenous compound devoid of significant toxicity. In particular, the present invention relates to a method of treating a patient affected by COVID-19 infection comprising administering an effective amount of a mixture of ultra-micronized palmitoylethanolamide and micronized palmitoylethanolamide to said patient.

Method for the treatment of COVID-19 infections with palmitoylethanolamide

A composition of acylethanolamides is obtained from olive oil fatty acids and is used in treating neuroinflammation. The acylethanolamide complex includes (weight percentages): A method obtains the acylethanolamide complex and formulations contain the acylethanolamide complex.

Composition of acylethanolamides from olive oil fatty acids

Described herein is a composition based on N-palmitoyl-ethanolamide and Rutin in co-micronized form. In particular, a composition includes a mixture of palmitoyl-ethanolamide (PEA) and Rutin in co-micronized form in which the PEA/Rutin ratio is between 10:1 and 1:1. Pharmaceutical formulations for the treatment of humans and animals are also described. The composition is useable for the treatment of diseases of arteries and arterioles.

Composition of N-palmitoyl-ethanolamide and Rutin in co-micronized form

The present invention relates to an N-palmitoyl-D-glucosamine-based composition in a micronized form, optionally in combination with Curcumin. In particular, the present invention relates to N-palmitoyl-D-glucosamine in a micronized or co-micronized form with Curcumin. Such a product can be formulated in human or veterinary pharmaceutical compositions, dietetic products, food supplements, or foods for special medical purposes (FSMP), or in feeds, or nutritional supplements for animals for the treatment of chronic systemic inflammatory diseases, in humans and animals, resulting from dysfunctions of epithelia and synovial membranes.

N-palmitoyl-D-glucosamine in a micronized form

Described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.

Use of a combination of Adelmidrol and hyaluronic acid in the treatment of pain caused by osteoarthritis and epithelial dysfunctions

The synthesis of a series of Polyethylene glycol conjugates (esters and carbonates) of PEA and its analogous acylethanolamides, have higher water solubility and good hydrophilic/lipophilic balance, resulting in (i) improved accumulation in tissues (particularly skin and mucosae), (ii) prolonged release, and (iii) increased bioavailability. Improvement of PEA and analogous acylethanolamides levels in the tissues&#x2014;particularly in the skin and mucosae&#x2014;and their prolonged release is due to the improved bioavailability of related conjugates. Conjugates are able to extend the time frame in which PEA and analogous acylethanolamides exert their pharmacological effects.

Polyethylene glycol derivatives of palmitoylethanolamide and analogous acylethanolamides

The present invention regards compositions and methods for the modulation of amidases capable of hydrolyzing N-acylethanolamines useable in the therapy of inflammatory diseases. In particular, the present invention regards a compound of general formula (I): enantiomers, diastereoisomers, racemes and mixtures, polymorphs, salts, solvates thereof, wherein: (a) R is a linear alkyl radical having 13 to 19 carbon atoms or alkenyl radical having 13 to 19 carbon atoms carrying a double bond; (b) X is 0 or S; (c) Y is a 2 or 3 carbon atom alkylene residue, optionally substituted with one or two groups equal or different from each other and selected from among the group consisting of: &#x2014;CH, &#x2014;CHOH, &#x2014;COOCH, &#x2014;COOH. Y may preferably be: &#x2014;CH&#x2014;CH&#x2014;, &#x2014;CH&#x2014;CH&#x2014;CH&#x2014;, CH(CH)&#x2014;CH&#x2014;, &#x2014;CH&#x2014;CH(CH)&#x2014;, &#x2014;CH&#x2014;C(CH)&#x2014;, &#x2014;CH&#x2014;CH(CHOH)&#x2014;, &#x2014;CH&#x2014;C((CHOH))&#x2014;, &#x2014;CH&#x2550;CH&#x2014;, &#x2014;CH&#x2014;CH(COOCH)&#x2014;, &#x2014;CH&#x2014;CH(COOH)&#x2014;, for use as a medicine. 

Compositions and methods for the modulation of specific amidases for N-acylethanolamines for use in the therapy of inflammatory diseases

A therapy for renal diseases characterized by alterations of the kidney function, such as Chronic Kidney Disease (CKD), acute and chronic renal impairment, and renal diseases that develop in diabetic patients or in patients who underwent an anticancer chemotherapic treatment with a platinum derivative. The invention is a combination of compounds selected from mono- or diamide of a C12-C20 monocarboxylic acid, saturated or monounsaturated, or a C4-C14 dicarboxylic acid, saturated or monounsaturated, with an aminoalkanol, and compounds selected from Silymarin, derivatives thereof or conjugates or complexes thereof, for use in the treatment of renal diseases. The mono- or diamide of a C12-C20 monocarboxylic acid, saturated or monounsaturated, or of a C4-C14 dicarboxylic acid, saturated or monounsaturated, with an aminoalkanol and said Silymarin, derivatives thereof or conjugates or complexes thereof are formulated for a separate, sequential, concomitant administration or in admixture, also in a co-micronized or co-ultra-micronized form.

Combined use of amides of mono- and dicarboxylic acids and silymarin in the treatment of renal diseases

A method for making a flexible and clear plastics material article of manufacture having a low electric surface resistance, starting from a plastics material having a higher electric surface resistance, in which the electric surface conductivity of the starting article of manufacture is modified by partially including, into at least a portion of the outer surface of the article, carbon nanotubes. With respect to conventional methods, the inventive method allows to modify the starting plastics material electric surface resistance so as to lower it to values smaller than 10k&#x3a9;/sq, even starting from articles having a higher resistance of the order of 10k&#x3a9;/sq, while preserving the starting clearness and flexibility thereof.

Method for making a flexible and clear low surface electric resistance plastics material article of manufacture and the plastics material article made thereby

The present invention relates to a composition for pharmaceutical or veterinary use, comprising palmitoylethanolamide. In particular, the present invention relates to a pharmaceutical composition for human or veterinary use, containing a therapeutically efficient amount of palmitoylethanolamide in the ultra-micronized form, wherein more than 90% by weight of palmitoylethanolamide has particle sizes lower than 6 microns, together with pharmaceutically acceptable excipients.

Compositions containing ultra-micronized palmitoyl-ethanolamide

Composition containing ultra-micronized palmitoyl-ethanolamide

Optionally O-substituted glycero-phosphoinositol derivatives, their analogues and their salts wherein the substitutents: R'1, R&#x2032;2, R2, R3, R4, R5, R6 have the described meaning, their synthesis and their pharmacological effect as modulators of the activation or over-stimulation of cPLA2.

Glycerophosphoinositol derivatives as modulators of cytosolic A2 phospholipase

The present invention relates to the use of N-acylvanillinamide derivatives capable of activating the peripheral receptor CB1 of cannabinoids. In particular, the present invention relates to the use of compounds of general formula (I) in which the meanings of R, R, Rand Y are as defined in the description, for the preparation of a medicinal product which is capable of activating the peripheral receptor CB1 of cannabinoids.

N-acylvanillinamide derivatives capable of activating peripheral cannabinoid receptors

The present invention relates to novel covalent derivatives of alkanolamides of monocarboxylic and dicarboxylic acids with aminoalcohols of general formula (I) which can usefully be used as agonists of the CB2 cannabinoid receptor and hence as drugs active in pathological conditions which can be controlled by stimulation and/or costimulation of this receptor

Covalent derivatives of alkanolamides of monocarboxylic and dicarboxylic acids functionally active on the CB2 cannabinoid receptor

The present invention relates to a method for treating eosinophilic granuloma in a Feline comprising administering a pharmaceutical composition, the composition comprising N-palmitoylethanolamide. The present invention also relates to said pharmaceutical composition and the process for the preparation thereof.

Pharmaceutical compositions containing N-palmitoylethanolamide and use thereof in the veterinary field

Growing community of inventors

Due Carrare, Italy

Gabriele Marcolongo